Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMedOpen access

Intra-articular and intra-osseous expanded adipose-derived stromal cell injections for knee osteoarthritis-related bone marrow lesions yield promising outcomes: Preliminary results in 16 athletes.

Khoury MA., Papakostas ET., Marín Fermín T., Tabben M., Chamari K., Levi L.

Laboratory Study on Knee Osteoarthritis, Osteoarthritis, published in J Exp Orthop (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
J Exp Orthop (2026)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
41541548
PMCID
PMC12802558
DOI
10.1002/jeo2.70527

Abstract (original English)

To explore the results of a fluoroscopic-guided intra-osseous (IO) and intra-articular (IA) injection of expanded adipose-derived stromal cells (ASCs) in athletes with bone marrow lesions (BML) associated with knee osteoarthritis (OA). A prospective study was conducted on 16 athletes (9 males, 7 females; mean age 30.5 ± 2.8 years), including two with bilateral knee involvement. All had Kellgren-Lawrence grades 2-4 and received IA and IO injections of 24.3 ± 2.1 million and 23.4 ± 1.9 million ASCs, respectively. Clinical outcomes were assessed using the Knee Injury and Osteoarthritis Outcome Score (KOOS), Numeric Pain Rating Scale (NPRS), and Tegner activity scale at baseline, 6 months, and 12 months. Radiological changes were evaluated using Magnetic Resonance Imaging Osteoarthritis Knee Scores (MOAKS) at baseline and 12 months. Significant improvements were observed in NPRS, Tegner, and all KOOS subscales at 6 months and 12 months with respect to baseline ( p < 0.05). At 12 months, NPRS decreased from 6.6 ± 0.9 to 2.4 ± 0.5, and Tegner increased from 4.4 ± 1.8 to 7.8 ± 1.1. All KOOS subscale scores improved at 12 months. Symptoms: 49.3 ± 6.4 to 74.1 ± 4.9; pain: 49.4 ± 4.3 to 75.8 ± 3.2; sport and recreation: 30.6 ± 6.2 to 67.8 ± 4.3; activities of daily living: 57.6 ± 3.6 to 79.9 ± 4.8; and quality of life: 35.4 ± 10.3 to 66.3 ± 5.3. A mild decline yet significant in the KOOS

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research